Immuno-Oncology June 2, 2021

YORBA LINDA, Calif. (PRWEB)
May 27, 2021

Labroots, the leading scientific social networking website, offering premier, interactive virtual events and webinars, today announced its 2nd annual Immuno-Oncology scientific event to be held on June 2nd, 2021. Free to attend for all participants, Immuno-Oncology 2021 is the premier meeting addressing the rapid advancements in immuno-oncology to further expand the knowledge of therapeutics for a wide range of cancers.

This prestigious forum will bring together thousands of innovative researchers, clinicians, oncologists, top scientists, healthcare professionals and leading academia and industry experts on a global basis. The educational presentations will be delivered by some of the brightest minds in the field of immuno-oncology while delving into sessions on new advancements in immuno-oncology, emerging targets for immuno-oncology therapy, and advancing cancer immunotherapies to the clinic.

A full speaker line up aimed to foster renewed exchange and unveil novel research findings on topics such as cell therapy innovation, characterizing CAR T cell responses to low density antigens, engineering universal chimeric antigen receptors for cancer therapy, overcoming obstacles in the immunosuppressive tumor micro-environment, novel cell therapy targets and engineering strategies, industry response to the expanding need in immuno-oncology for validated antibodies, fueling antitumor immunity using oncolytic viruses encoding metabolic modulators, Th17-inducing vaccines for the treatment of ovarian cancer and much more, provides an informative agenda you won’t want to miss!

Notably, two stellar keynote deliveries highlight the day including well-renowned experts, Dr. Gordon Freeman, Professor of Medicine, Harvard Medical School addressing new checkpoints and biomarkers, followed by Dr. Michael A. Curran, Associate Professor of Immunology, MD Anderson Cancer Center, The University of Texas describing the impact of hypoxia on tumor immunity and the approaches for reducing tumor hypoxia.

“The foundational role of immuno-oncology in current cancer therapy has been built on antibodies which block the “checkpoint” switches engaged by tumors to locally silence the T cells seeking to eradicate them,” said Dr. Michael Curran, Associate Professor of Immunology, MD Anderson Cancer Center, University of Texas. “While these drugs have been transformational for patients with more immune exposed cancers such as melanoma and lung cancer, the majority of patients overall still derive little benefit from immunotherapy due to a lack of pre-existing immune infiltration of their cancers. In the Labroots Immuno-Oncology Virtual Event, you will see how critical metabolic checkpoints act to orchestrate these immune “cold” and immunotherapy resistant tumor microenvironments, and how interventions which have the potential to normalize the metabolic environment of these cancers can re-sensitize them to immune infiltration and, ultimately, elimination.”

Greg Cruikshank, Chief Executive Officer at Labroots said, “We are delighted to host and produce this event for its second consecutive year to showcase future directions for innovative research and help move the field of cancer immunology and immunotherapy forward. As one of the most promising areas of cancer research, coupled with bringing together prominent industry and academic speakers under one roof to share insights and accelerate the discovery to fight cancer, Labroots is committed to drive breakthroughs in this field via our recognized platform.”

Produced on Labroots’ robust platform while connecting across all desktop and mobile devices, the interactive environment encompasses a lobby, auditorium featuring live chatting during keynote, and sponsored sessions, poster hall, exhibit hall (driving innovations and highlighting the latest array of products and technologies), and networking lounge allowing an enriched learning experience for all participants. As an approved provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. Program, Labroots offers participants the opportunity to earn 1 Continuing Education Credit per presentation for a maximum of 30 credits.

To register for the event, click here. Join the online conversation and use the official event hashtag #LRimmuno to stay up to date on the latest information.

About Labroots

Labroots is the leading scientific social networking website, and primary source for scientific trending news and premier educational virtual events and webinars and more. Contributing to the advancement of science through content sharing capabilities, Labroots is a powerful advocate in amplifying global networks and communities. Founded in 2008, Labroots emphasizes digital innovation in scientific collaboration and learning. Offering more than articles and webcasts that go beyond the mundane and explore the latest discoveries in the world of science, Labroots users can stay atop their field by gaining continuing education credits from a wide range of topics through their participation in the webinars and virtual events.

Share article on social media or email:

Dr. Vitenas

“Dr. Vitenas is AMAZING!” wrote one satisfied patient. “I was very confident after my consultation that I would get my desired goal with him as my surgeon, and I definitely did! I’m so happy with the results!”

HOUSTON (PRWEB)
May 27, 2021

Vitenas Cosmetic Surgery is proud to announce that their own Dr. Vitenas, M.D., F.A. C. S., has been selected as a Castle Connolly Top Doctor for 2021. The award is a physician-led elite recognition and adds to a long list of previous peer-led recognition and awards that Dr. Vitenas has received.

Castle Connolly has served as the official source of the nation’s top doctors for over 25 years. The Castle Connolly Top Doctor distinction is an exclusive elite recognition in which physicians are nominated by their peers based on an extensive list of criteria. Castle Connolly’s physician-led research team then screens every nomination to ensure their Top Doctors meet their high standards.

“It’s an honor to have been selected again as a Castle Connolly Top Doctor”, said Dr. Vitenas. “Plastic surgery is an art form and I focus on delivering a natural result.” he continued. “And there have been many artists throughout the ages, but very few Picassos and Monets. What is it that makes their work so enduring? It is the natural result that they produced. The true beauty in the human form is a natural look and that is what you can expect at Vitenas Cosmetic Surgery.”

In addition to the 2021 Top Doctor recognition, Dr. Vitenas has received a long list of accolades including being named a Real Self Top Doctor for Breast Augmentation, membership among the elite Texas Super Doctors, Castle Connolly Top Doctor 2019, and 2015 Best of Med Aesthetics. In addition, Dr. Vitenas is a board-certified physician with licensure to practice in Texas, Louisiana and Florida and is a member of the American Society of Plastic Surgeons.

The work of Dr. Vitenas and his team have amassed thousands of five-star online reviews with patients who share their experience with enthusiasm.

“Dr. Vitenas is AMAZING!” wrote one satisfied patient. “I was very confident after my consultation that I would get my desired goal with him as my surgeon, and I definitely did! I’m so happy with the results!”

Dr. Vitenas believes in the power of real-world results and urges anyone interested in aesthetic surgery to visit his practice’s website at http://www.drvitenas.com to view the results that his practice has achieved for patients over the years.

About Vitenas Cosmetic Surgery

At Vitenas Cosmetic Surgery, our sole focus is dedicated to the fine art of plastic surgery. We strive to create beautiful, proportionate, natural-looking aesthetic results for each patient who comes into our office. Our practice professionals regularly receive awards and recognition in Top Doctor, Real Self, Texas Super Doctors and more. To learn more about our work, we recommend you begin by viewing our extensive before and after library located on our website, http://www.drvitenas.com.

Share article on social media or email:

RAPID NOVOR Mass Spectrometry Lab

This is the first time in the world that animal polyclonal antibodies have been de novo sequenced successfully purely from protein.

KITCHENER, Ontario (PRWEB)
May 27, 2021

Rapid Novor Inc., the world’s leader in antibody protein sequencing using mass spectrometry, announced today that it has reached a major milestone in the life sciences industry by being the first to successfully sequence polyclonal antibodies directly from proteins without DNA sequencing data. The team sequenced a pool of antibody proteins purified from the blood of immunized rabbits using only proteomics.

This remarkable feat represents a successful validation of Rapid Novor’s novel antibody discovery platform utilizing REpAb® sequencing technology. The results of the technology are already helping to develop new diagnostic tests and will be utilized to establish novel antibody therapies.

This is another major milestone of Rapid Novor’s R&D in decoding the immune system by sequencing the antibody proteome. The antibody proteome encompasses all antibodies expressed in the blood and is hence a more accurate representation of the functional immune response repertoire, unlike the genome, which contains a relatively static set of instructions for protein expression.

“This is the first time in the world that animal polyclonal antibodies have been de novo sequenced successfully purely from protein. ” said Mingjie Xie, CEO of Rapid Novor Inc. “Decoding the proteome is critical to enabling next-generation therapeutics, and to fully understand our bodies response to diseases. Without looking at the final products of the immune response, it’s not always clear what the body has chosen as the best tools to fight off disease.” The company’s proteomics-based antibody discovery technology unlocks this previously understudied area, enabling an entirely new way to explore the immune system. In collaboration with biotech companies around the world, Rapid Novor’s REpAb® platform allows discovery of previously “unseen” antibodies that can be used to treat diseases for which treatments have been difficult to find.

Matt Pope, VP of Client Services of SISCAPA Assay Technologies Inc. (Victoria, British Columbia) explained; “Rapid Novor was tasked with finding highly specific, high affinity antibodies against an important target- and they delivered powerful antibodies fit-for-purpose. Such antibodies are not easily obtained yet the Rapid Novor approach proved immediately successful, despite our time-constrained and stringent demands.”

Rapid Novor continues to work with companies in the biotech and pharmaceutical industries to tackle some of the most challenging healthcare problems. By developing specific antibody reagents in oncology, vaccinology, and autoimmune disease as part of their pipeline, Rapid Novor aims to scale up their business in the coming years and grow their next-generation protein sequencing technology.

About Rapid Novor Inc.

Rapid Novor Inc., is the world’s leader in antibody protein sequencing technology. Specializing in the field of mass spectrometry-based proteomics, the team has developed the technology to directly sequence antibody proteins without needing access to the producing cell line. Located at the Kitchener-Waterloo high-tech hub, the company continues to build its technology portfolios based on over years of scientific research and inventions. The company’s mission is to advance life science for better human health with next generation protein sequencing. For more information, please visit http://www.rapidnovor.com. Follow the company on Twitter @rapidnovor or LinkedIn https://www.linkedin.com/company/rapid-novor-inc/.

About SISCAPA Assay Technologies, Inc.

SISCAPA Assay Technologies, Inc. is a protein quantitation/diagnostics company based in Washington DC and Victoria BC. that develops SISCAPA immuno-mass spectrometric assays for high-value protein biomarkers and other proteins to enable precise measurement of human proteins in clinical and other samples.

Share article on social media or email:

On Syndicated Talk Show, The Doctors; A Community Rallies to Helps Woman Who Needs a Kidney

An innovative program, known as a paired kidney exchange, sometimes called a “kidney swap”, can still result in a suitable donor even when the living kidney donor is incompatible with their chosen recipient. Visit the National Kidney Foundation for more information.

PORT CHESTER, N.Y. (PRWEB)
May 27, 2021

Liz Rotfeld, a resident of Port Chester who needs a kidney transplant, can be seen on the Emmy® award-winning talk show The Doctors, which aired May 26th on CBS. The primary reason that Liz agreed to appear on the show is because she wants to share the importance of the early detection of kidney disease with as many people as possible.

More than two decades ago, Lizzie was diagnosed with IgA nephropathy, a chronic kidney disease caused by deposits of immunoglobulin A [IgA], a protein inside the filters of the kidney. It could be said that the findings were revealed many years after they “should have been.” As many women do, Liz had always put her own health on the back burner – her priorities were taking care of her family and devoting most of her time and energy to helping other people in her community.

Liz makes the crucial point that there is blood screening available that can detect specific proteins, such as IgA, that at certain levels cause kidney disease. Sadly, this test is not routinely performed when one undergoes common annual bloodwork. “If you have symptoms, such as frequent urinary tract infections or blood in urine, please request this test to be run on your bloodwork panel,” Liz implores.

The most common signs and symptoms of chronic kidney disease include:

• anemia
• blood in urine
• dark urine
• decreased mental alertness
• decreased urine output
• edema – swollen feet, hands, and ankles
• fatigue [tiredness]
• hypertension [high blood pressure]

Liz also shared some nutritional guidelines regarding foods to be avoided by those prone to kidney disease, including animal protein, foods high in sodium, and foods high in potassium, such as bananas, avocados, potatoes, and tomato paste.

There are a number of reasons why Liz is still waiting for a donor, and it’s not for lack of willing friends and family. Liz explains, “You don’t just go on a list, your kidneys need to be at a certain function to be on the list.” The willingness of the potential donors is just one facet of what can be a very arduous process. Her brother was the first to step up, but because he had undergone a surgery of his own and subsequently had issues with one of his kidneys, he was unable to help Liz, despite his readiness to donate. Two cousins and a friend were tested but became ineligible to donate due to ensuing complications. While a donor need not be a match, it is very important that said donor be in excellent health to qualify.

Liz posted about her journey for a kidney transplant on Facebook and was moved by the results: a woman she knew back in high school sent her a private message offering help. On Labor Day Weekend 2020, the son of her ex-husband’s cousin [she had remained close to the extended family] contacted Liz to selflessly offer one of his kidneys. However, while he was undergoing the necessary testing to determine whether he could be a match, he fell ill with COVID and had to halt the testing process. Once the testing resumed in March 2021, having gone so far into the process, he was disqualified due to slightly elevated blood pressure.

The opportunity for Liz to get a kidney is not limited to finding a match. An innovative program, known as a paired kidney exchange, sometimes called a “kidney swap,” can still result in a suitable donor even when the living kidney donor is incompatible with their chosen recipient. If the willing donor matches another person on the waitlist, the person they are connected with moves right up the list. Two live donor transplants would then occur. The kidney exchange was instituted with the goal of increasing the donor pool by giving people who are unable to receive a kidney from a loved one or a friend a chance to still receive one through an exchange between other incompatible donor/recipient pairs.

Kidney Swaps are revolutionizing the organ donation system.

The link for the May 26th episode of The Doctors can be found here found here.

About Liz: Liz Rotfeld is a mom, a sister, and a dear lifelong friend to many. She volunteers in her community for multiple organizations. Prior to the pandemic, she ran a monthly soup kitchen at a local church in her community, and during the pandemic, she shopped for the elderly and accompanied them to their Covid vaccine appointments. Liz is working diligently to raise awareness of the importance of early detection of kidney disease while sharing knowledge of how to recognize common symptoms and encouraging people to request the appropriate blood tests if kidney disease is suspected. Connect with Lizzie and her group on Facebook.

About the KIDNEY SWAP Program:

Both candidates and donors are carefully evaluated and tested, both medically and psychologically, in order to ensure that the benefits for all involved outweigh the risks. It is important for both surgeries to be scheduled for the same time in case either donor were to change their mind at the time of surgery. Surgeries can take place at the same or different hospitals, though it is considered advantageous if the surgeries take place at the same hospital.

In the paired exchange, an incompatible donor/ recipient pair [such as a brother and sister that don’t have compatible blood types] are matched with another incompatible donor/recipient pair, for a literal “kidney swap,” in which each donor gives a kidney to the other person’s intended recipient.

About the NEAD™ Chain

A NEAD™ [Never Ending Altruistic Donor] chain starts with one non-directed [altruistic] potential donor. In this program, the non-directed donor gives to a person waiting for a transplant, and that recipient’s willing – but incompatible – donor gives to another person waiting, and so on.

Each living donor in this system gives to a stranger, and the chain of donors is kept going as long as possible.

Donating a kidney in Liz’s name would move her up the list to receive a kidney.

Share article on social media or email:

Barriers to Asians and Pacific Islanders in Science and Medicine Diversity Panel Logo

This diversity panel features a timely and intimate discussion of the interactions my fellow Asian colleagues have experienced in the laboratory and the clinic, stories that are unfortunately all too common,” said SITC President Patrick Hwu, MD.

MILWAUKEE (PRWEB)
May 27, 2021

The Society for Immunotherapy of Cancer (SITC), in collaboration with the Chinese American Hematologist and Oncologist Network (CAHON) and the Indo-American Cancer Association (IACA), is pleased to release an important diversity panel discussion of society leaders sharing their experience as Asians working in the cancer research field.

“Barriers to Asians and Pacific Islanders in Science and Medicine Diversity Panel,” is an hour-long group discussion, hosted by the SITC Diversity and Inclusion Task Force, featuring society leaders who open up to share personal and professional reflections as Asian and Pacific Islanders working as researchers and oncologists in the United States and Canada. Moderated by SITC Vice President and Task Force Co-chair Leisha Emens, MD, PhD; Task Force member Avery D. Posey, PhD; and CAHON Immediate Past President Lei Zheng, MD, PhD; the recorded webinar features discussion from the following Diversity Panel members:

• 
  Zihai Li, MD, PhD – Ohio State University
• Pamela Ohashi, PhD – Princess Margaret Cancer Centre
• Padmanee Sharma, MD, PhD – The University of Texas MD Anderson Cancer Center
• Weijing Sun, MD, FACP – University of Kansas Medical Center

“This diversity panel features a timely and intimate discussion of the interactions my fellow Asian colleagues have experienced in the laboratory and the clinic, stories that are unfortunately all too common,” said SITC President Patrick Hwu, MD. “While Asian-Americans have considerable representation in our field as a whole, reported data show us the extreme uphill climb most have to achieve leadership roles within the profession. Today’s discussion shines a light on some of those barriers that exist. I admire all of the panel participants for sharing personal stories, and I hope the experiences offered serve as a learning opportunity for leaders in institutions across our country.”

According to an October 2020 report in The Cancer Letter on workforce disparity, in 2018 approximately 26 percent of oncologists in the U.S. were Asian and Pacific Islanders, while only 11 percent sat as cancer center deputy or associate directors, and only 7 percent served as cancer center directors. The SITC-CAHON-IACA diversity panel featured discussion on a range of topics, including the importance of mentorship within the Asian-American community, experiences of seeking promotions within the field and the action SITC and other organizations can take to address barriers for minority groups in medicine and research. The panel discussion, which was recorded on Thursday, May 20, was also done so, in part, to honor Asian American and Pacific Islander Heritage Month, which concludes on Monday, May 31.

“We know the stories shared during our discussion are not limited to the participants on the panel, but also impact the broader community of Asian-Americans and other under-represented minorities. It is imperative for organizations like SITC to take the lead on improving awareness of, and identifying solutions for, professional barriers within our field for under-represented minorities,” said Dr. Emens. “I remain in awe of the courage shown by all of the panel participants, as their honesty and vulnerability will not only benefit the current biomedical community, but also generations of scientists and clinicians to come.”

The SITC-CAHON-IACA diversity panel discussion is available for on-demand viewing via the SITC YouTube channel.

About SITC

Established in 1984, the Society for Immunotherapy of Cancer (SITC) is a nonprofit organization of medical professionals dedicated to improving cancer patient outcomes by advancing the development, science and application of cancer immunotherapy and tumor immunology. SITC is comprised of influential basic and translational scientists, practitioners, health care professionals, government leaders and industry professionals around the globe. Through educational initiatives that foster scientific exchange and collaboration among leaders in the field, SITC aims to one day make the word “cure” a reality for cancer patients everywhere. Learn more about SITC, our educational offerings and other resources at sitcancer.org and follow us on Twitter, LinkedIn, Facebook and YouTube.

# # #

Share article on social media or email:

Zonez 10′ X 10′ Modular Meeting Room

“Zonez has created the first modular room I have seen that checks all the boxes. The room looks beautiful and the Zonez system is built to adapt to stringent code requirements. It is the most complete solution I have seen.” Mike PGeneral Contractor, Principal

ORANGE, Calif. (PRWEB)
May 27, 2021

Modular construction has grown in popularity over the past decade as companies appreciate the speed and cost benefits of modular construction. In the post pandemic world, modular rooms are now more popular than ever.

Zonez http://www.zonez.com, a division of Allied Modular http://www.alliedmodular.com, which has more than 30 years of experience, is announcing the launch of its new 10′ X 10′ modular collaboration suite. The Zonez Collaboration Suite connect easily to the real world by utilizing a proprietary air flow system and fully modular grid ceiling.

Beautiful design meets practical application with the new Zonez Collaboration Suite. “A majority of modular solutions are designed without construction and code compliance in mind. Most manufacturers live in Europe or design IKEA grade products which are offered direct to customers who do not understand code compliance in the US,” said Sande Golgart, President of Zonez.

Golgart added, “There are basic requirements that must be met in any room that include a minimum ceiling height, fire suppression and air flow. Most manufacturers do not meet the most basic interior height requirements. I have seen warehouses filled with expensive modular rooms from Europe that customers have spent hundreds of thousands of dollars on that cannot be installed due to these limitations.”

Zonez new line of modular solutions now enable companies to buy with confidence. Before you spend money on a modular solution, check to make sure the minimum requirements have been met by your manufacturer. For information about the International Building Code and other code requirements, contact Zonez at sales@zonez.com.

Zonez currently operates out of three facilities across the country.

For interview requests, please contact sales@zonez.com

For more about the innovative Zonez soundproof privacy solutions or to request a quote, click here: https://zonez.com/privacy-suites/

Share article on social media or email:

Greenlight Guru is continuing to push the ideal of harmonization and industry best practices forward through the formation of our Regulatory Advisory Board.

INDIANAPOLIS (PRWEB)
May 27, 2021

Greenlight Guru, the leading medical device quality management software platform, today announced the formation of its new Regulatory Advisory Board (RAB), comprised of nine veteran medical device professionals. Members of Greenlight Guru’s RAB have prior experience with regulatory bodies, including FDA and EU notified bodies, and have significant medical device industry expertise with respect to regulations, standards, and requirements impacting the medical device industry.

Medical device industry regulations, standards, guidelines and requirements evolve often, and expectations for medical device companies are increasing and ever-changing. Now more than ever, companies need guidance and solutions to navigate frequent industry changes on a global scale.

“While global harmonization is an ideal for the medical device industry, regulations throughout the various markets are still dynamic and not always in sync,” said Jon Speer, founder of Greenlight Guru. “The regulatory changes continually impact our industry. As such, Greenlight Guru is continuing to push the ideal of harmonization and industry best practices forward through the formation of our Regulatory Advisory Board.”

Collaborating with external medical device regulatory experts helps ensure Greenlight Guru, its customers, and the entire medical device industry have a channel for receiving the most up-to-date and best medical device industry intelligence regarding global regulations and requirements. As a result, Greenlight Guru products and services will not only continue to comply with the latest requirements but also stand out as best-in-industry entries. Greenlight Guru RAB members are actively involved with influencing and defining the regulations, standards, and requirements that impact medical device companies around the world. The RAB is a forum to discuss current industry issues and trends and identify needs for further education and information to help medical device companies, as well as regulatory bodies.

“This group has the potential to influence the direction of the medical device industry in some very significant ways,” said Greenlight Guru RAB member, Michael Drues, PhD, President of Vascular Sciences. “I look forward to being part of those discussions as we work to make the medical device industry and indeed the world a better place.”

The first nine members of Greenlight Guru’s RAB are:

• 
  Dr. Bassil Akra – CEO and Co-owner of QUNIQUE GmbH; EU MDR / IVDR expert
• Edwin Bills, ASQ Fellow, RAC – Consultant; 20-year Member, ISO TC 210 JWG1, the technical committee responsible for ISO 14971:2019 and ISO TR 24971:2020.ISO 14971 Standard Development Team Member
• Michael Drues, PhD – President of Vascular Sciences; expert in regulatory strategies, including FDA De Novo, 510(k), and breakthrough device program
• Eric Henry – Senior Quality Systems and Compliance Advisor at King & Spalding; expertise with software as a medical device (SaMD), AI and machine learning
• Allison Komiyama, PhD, RAC – Principal Consultant at AcKnowledge Regulatory Strategies; former FDA reviewer and expertise with FDA breakthrough device program and 510(k) submissions
• Evangeline Loh – VP of Regulatory Affairs at EMERGO by UL; experienced with global regulatory processes
• Steve Niedelman – Lead Quality Systems and Compliance Consultant at King & Spalding; expertise with FDA inspections, including post-inspection followup
• Peter Sebelius – Founder of Medical Device HQ; CEO and Consultant at Gantus AB; Member, ISO TC 210 JWG1, the technical committee responsible for ISO 14971:2019 and ISO TR 24971:2020.
• George Zack – Co-founder and Principal at Two Harbors Consulting; Lead Appraiser for FDA’s Case for Quality initiative

To stay up to date with the Greenlight Guru Regulatory Advisory Board, subscribe to our newsletter http://www.greenlight.guru/newsletter.

###

About Greenlight Guru

Greenlight Guru is the only quality management software platform designed specifically for medical device companies. The platform helps companies bring safer products to market faster, simplifies FDA and ISO regulatory compliance and provides a single source of truth by connecting the management of all quality processes like CAPAs, risk, audits and more. Greenlight Guru’s platform is used by thousands of users across the globe to push beyond baseline compliance and achieve True Quality for their medical devices. For more information, visit http://www.greenlight.guru.

Media Contact

Kate Johnson

kate_johnson@blastmedia.com

(317) 806-1900

Share article on social media or email:

The entire Aniara line is available for purchase at http://www.aniara.comM

WEST CHESTER, Ohio (PRWEB)
May 27, 2021

Aniara Diagnostica, a multi-national distributor of diagnostic and research agents, as well as screening tools, has strengthened its commitment to meeting today’s highest standards for product quality and cost-efficient delivery.

For Research Use Only. Not for Use in Diagnostic Procedures.

Buffered Sodium Citrate is used in clinical laboratories, venous blood collection tubes and in blood banks as an effective anti-coagulant, usually in a ratio of 1:9 sodium citrate/blood. The citrate ion chelates calcium ions in the blood by forming calcium citrate complexes and disrupting the blood clotting mechanism.

A12-8480-10 Buffered Sodium Citrate 3.2% (0.109 M) (100 mL) (10 pouches) click here for more information

A12-8483-5 Buffered Sodium Citrate 3.2% (0.109 M) (1000mL) (5 pouches) click here for more information

The entire Aniara product line is available for purchase at http://www.aniara.com. The Company distributes products in North America, Central America, South America, Sweden, Norway, Denmark, Finland, Lithuania, Latvia, Estonia and Iceland.

Share article on social media or email: